Metastatic Breast Cancer
Conference Coverage
Treating bone loss ups survival for breast cancer patients
Findings suggest a trend toward reduction in contralateral breast cancer in the treatment group.
Conference Coverage
Pembrolizumab before surgery improves survival in early triple negative breast cancer
Treatment shifts residual cancer burden to lower categories.
Conference Coverage
New treatment outperforms chemo in HER2-low breast cancer
The results may cause clinicians to reconsider how they define HER2 expression in breast cancer.
Conference Coverage
New treatment meets unmet need in breast cancer
Expert calls advance incremental, but clinically important for women with HR positive/HER2 negative breast cancer.
Conference Coverage
ctDNA spots breast cancer recurrence
Personalized surveillance technique has the potential to augment adjuvant therapy and improve long-term outcomes.
From the Journals
Neoadjuvant denosumab ineffective in breast cancer
Trial returns a negative result for the RANKL inhibitor, but identifies favored schedule for nab-paclitaxel.
From the Journals
‘Unlimited’ cancer costs: The Medicare Part D dilemma
Many patients with cancer who rely on Medicare Part D face an impossible choice: “Your money or your life.”
From the Journals
Sex hormones linked to breast cancer in men
Finding could point to a role for sex hormones, but more work needs to be done.
Conference Coverage
Quadruple-negative breast cancer associated with poorest outcomes
Patients lacking PD-L1 expression responded less to chemotherapy and had poor prognoses.
From the Journals
Mastectomy may not be necessary for young breast cancer patients
Treatment with mastectomy versus lumpectomy had no impact on survival, shows study.
Conference Coverage
Twenty years and counting: Tamoxifen’s lasting improvement in breast cancer
Study suggests long-term improvement for some women with breast cancer.